Table 6.
Sensitivity analysis of studies with more than 100 patients on Patient-level analysis and Lesion-level analysis
| Study ID | Patient-level analysis | Lesion-level analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| Median | Lower Quartile | Upper Quartile | Median | Lower Quartile | Upper Quartile | |||
| NBI vs WLC (n=2) | NBI vs WLC (n=3) | |||||||
| Sensitivity | 100 | - | - | 92.86 | 90.08 | 95.63 | ||
| Specificity | 65.78 | - | - | 76.85 | 73.01 | 81.58 | ||
| Positive predictive value | 76.63 | - | - | 68.42 | 61.17 | 71.79 | ||
| Negative predictive value | 100 | - | - | 100 | 98.82 | 100 | ||
| False positive rate | 33.53 | - | - | 23.15 | 18.42 | 26.99 | ||
| False negative rate | 0 | - | - | 7.14 | 4.37 | 9.92 | ||
| HAL vs WLC (n=1) | HAL vs WLC (n=4) | |||||||
| Sensitivity | 83.33 | - | - | 92.19 | 91.48 | 92.97 | ||
| Specificity | 92.75 | - | - | 85.74 | 77.33 | 87.42 | ||
| Positive predictive value | 80 | - | - | 73.26 | 70.05 | 77.94 | ||
| Negative predictive value | 93.81 | - | - | 96.13 | 91.70 | 99.68 | ||
| False positive rate | 7.25 | - | - | 14.26 | 12.58 | 22.67 | ||
| False negative rate | 16.67 | - | - | 6.84 | 5.24 | 7.65 | ||
| 5-ALA vs WLC (n=2) | 5-ALA vs WLC (n=2) | |||||||
| Sensitivity | 89.67 | - | - | 94.42 | - | - | ||
| Specificity | 75.05 | - | - | 80.28 | - | - | ||
| Positive predictive value | 77.65 | - | - | 66.33 | - | - | ||
| Negative predictive value | 75.47 | - | - | 98.25 | - | - | ||
| False positive rate | 24.96 | - | - | 19.72 | - | - | ||
| False negative rate | 10.33 | - | - | 5.58 | - | - | ||
NMIBC: non-muscle-invasive bladder cancer; WLC: white light cystoscopy; 5-ALA: 5-aminolaevulinic acid; HAL: hexylaminolevulinate; NBI: narrow band imaging; NR: not reported.